Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
European Urology Focus|April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based CombinationsGeorges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open|June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate CancerGabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
Frontiers in Oncology|April 30, 2020
Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling AxisMarion Vanneste, Charlotte R Feddersen, Afshin Varzavand, et al.
Head & Neck|July 14, 2016
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanomaRobert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, et al.
Plos One|March 7, 2017
Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44Deborah Wessels, Daniel F Lusche, Edward Voss, et al.
Pageof 21